Innovative Biotech

What Innovative Biotech does

Innovative Biotech Limited (founded 2006 in Nigeria by Dr. Simon Agwale) is a pre-revenue African virology and vaccinology company building Nigeria's first end-to-end cGMP vaccine manufacturing facility in Keffi, Nasarawa State. The facility is designed for an annual capacity of 225 million doses, targeting routine and outbreak vaccines for typhoid, rotavirus, HPV, polio, hexavalent combinations, pneumococcal disease, and cholera, with a pipeline extending to COVID-19, HIV, Ebola, HPV, and Lassa.

The company's core technology is a proprietary virus-like-particle (VLP) platform that can express multiple viral proteins beyond the Spike protein and mix vaccines across variants, complemented by Merck-supplied Mobius single-use fill-and-finish infrastructure. Innovative Biotech holds owned IP for Ebola and HIV vaccines (proven in animal studies), an exclusive global license for a COVID-19 VLP vaccine from TechnoVax, and in-licenses from Bharat Biotech for already-approved Typhoid and Rotavirus vaccines. In parallel, it sells three consumer health supplements (Nano Silver, Immune Builder, Daily Multiple) directly through its e-commerce site at ₦40,000–₦60,000 per unit.

The business model blends B2G/enterprise vaccine contracts with government health programs (NCDC, Federal Ministry of Health, Presidency of Nigeria), future regional distribution across African healthcare systems, and a small D2C supplement stream. Revenue mechanics include one-time vaccine sales, contract manufacturing services, diagnostics services, licensing royalties on the COVID-19 VLP IP, and unit-priced D2C supplements. Strategic partners include Merck (technology/facility design), Afreximbank (Project Preparation Facility financing), Bharat Biotech (vaccine licenses), and the International Trade Centre (ecosystem support). The firm reports 1–10 employees and no public revenue, and the manufacturing facility has not yet commenced commercial production.

Name

Innovative Biotech

Legal name

Innovative Biotech Limited

Website

https://innovativebiotechng.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

Innovative Biotech is a Nigerian biotech building Nigeria's first end-to-end vaccine manufacturing facility (225M-dose capacity) using a proprietary VLP platform, licensed and in-house vaccines, and partnerships with Merck, Afreximbank, and Bharat Biotech.

Ownership category

akta.pro rank

Product category

Vaccine Manufacturing and Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industry

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

Keywords

• Vaccine manufacturing
• Biologics contract manufacturing
• Diagnostic services
• Health supplements
• Vaccine distribution

Headquarters

HQ city

Anambra

HQ country

Nigeria

HQ region

Africa

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Infrastructure, Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Vaccine Sales: Sale of domestically manufactured vaccines including Typhoid Conjugate Vaccine, Rotavirus, HPV, IPV, Hexavalent, PCV, and Cholera vaccines to government health programs and healthcare providers across Africa.
2. Contract Manufacturing Services: Contract manufacturing services for pharmaceutical companies and organizations looking to outsource production of vaccines and biologics, utilizing state-of-the-art facilities and expert teams.
3. Diagnostics Services: Comprehensive diagnostic services for detecting and identifying various diseases and conditions using advanced technologies and expertise.
4. Consumer Health Supplements: Direct-to-consumer sales of health supplements including Nano Silver, Immune Builder, and Daily Multiple through e-commerce platform.
5. Licensing Royalties: Revenue from exclusive global license for COVID vaccine and intellectual property licensing for Ebola and HIV vaccines with proven efficiency in animal studies.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Innovative Biotech manufactures a portfolio of vaccines targeting Typhoid, Rotavirus, HPV, Polio, Hexavalent, Pneumococcal, and Cholera diseases, and distributes consumer health supplements (Nano Silver, Immune Builder, Daily Multiple) through its own e-commerce platform. The company also provides diagnostics, contract manufacturing for vaccines and biologics, and R&D services using its proprietary VLP vaccine platform.

Product overview

Innovative Biotech is a biotechnology company focused on vaccine development, manufacturing, and health supplements in Africa. The company operates a multi-product portfolio consisting of seven vaccine products (Typhoid Conjugate Vaccine, Rotavirus Vaccine, HPV 2, Inactivated Poliomyelitis Vaccine, Hexavalent vaccine, PCV 14, and Cholera vaccine) developed through licensing agreements with Bharat Biotech and its own VLP-based vaccine technology, alongside three health supplement products (Nano Silver, Immune Builder, Daily Multiple) sold directly to consumers. The company also provides diagnostic services, contract manufacturing, and research and development services. The vaccine manufacturing facility in Keffi, Nasarawa State, Nigeria aims to produce up to 225 million doses annually.

Differentiator

Problem solved

Functional benefit

Products and services

• Typhoid Conjugate Vaccine (Typbar TCV) A vaccine targeting typhoid disease, included in Innovative Biotech's vaccine portfolio and supplied for public immunization programs in Africa.
• Rotavirus Vaccine (Rotavac) A vaccine targeting rotavirus disease, included in Innovative Biotech's vaccine portfolio for public immunization programs.
• Human Papilloma Virus Vaccine (HPV 2) A vaccine targeting human papillomavirus, included in the vaccine portfolio for public immunization programs.
• Inactivated Poliomyelitis Vaccine (IPV) A vaccine targeting polio, included in the vaccine portfolio for routine immunization programs in Africa.
• Hexavalent Vaccine (EASY SIX) A hexavalent combination vaccine included in the vaccine portfolio, designed to provide protection against multiple diseases in a single dose.
• PCV 14 (PNEUBEVAX) A 14-valent pneumococcal conjugate vaccine included in Innovative Biotech's vaccine portfolio for pneumonia prevention.
• Cholera Vaccine (CHOLVAX) A vaccine targeting cholera disease, included in the portfolio for public health deployment and outbreak response.
• Nano Silver A health supplement priced at ₦40,000 per unit that boosts immune system functions, aids natural defense against bacteria, supports healthy gut function, and aids inflammatory response.
• Immune Builder A health supplement priced at ₦50,000 per unit designed to build the immune system and support overall health and wellbeing, featuring clinically-proven ingredients and an unmatched absorption enhancer.
• Daily Multiple A comprehensive health supplement priced at ₦60,000 per unit containing vitamins A, B1-B12, C, D, E, macro minerals, 72+ trace minerals, 15+ amino acids, and digestive enzymes to support enzyme functions, tissue repair, and breakdown of carbs, fats, and proteins.
• Diagnostics Services Comprehensive diagnostic services for detecting and identifying various diseases and conditions using advanced technologies and expertise to provide accurate and reliable diagnostic solutions to aid timely medical interventions.
• Contract Manufacturing Services Contract manufacturing services providing pharmaceutical companies and organizations with reliable and efficient production solutions using state-of-the-art cGMP-compliant facilities and expert teams for the manufacturing and packaging of vaccines and biologics.
• Research & Development Services R&D services at the core of operations encompassing vaccine development, diagnostics, and therapeutic interventions, investing in scientific exploration and discovery to advance medical knowledge and develop novel healthcare solutions.

Quantifiable outcome

• 225 million doses annual production capacity for Typhoid, Rotavirus, Pentavalent/Hexavalent, and future vaccines including COVID-19, HIV, Ebola, HPV, and Lassa
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core, flagship and minor.

• North Central Development Commission (NCDC)coreStrategic or Co-development Partner · 1 November 2025Strategic partnership for advancing public health security across North Central region. Focus on deployment of Typhoid Conjugate Vaccine (TCV) and Cholera vaccines to address public health challenges in underserved communities. Both parties agreed to establish technical working group for implementation including vaccine deployment logistics, awareness campaigns, and regional capacity building.
• Merck (Germany)coreTechnology or Integration · 21 December 2021Merck signed an agreement with Innovative Biotech to design the manufacturing process for the first vaccine production facility in Nigeria. Merck provides technical support, facility design expertise using Mobius single-use technology, and access to equipment manufacturers. First phase focuses on fill-and-finish facility design, second phase enables continuous manufacturing. Part of West African pandemic readiness program.
• TechnoVaxcoreTechnology or IntegrationInnovative Biotech's licensor developing VLP-based COVID-19 vaccine targeting variants. TechnoVax received Life Science's Advance Biotech Grant in 2019 for developing virus-like particle platform for respiratory diseases, hemorrhagic fevers, immunodeficiency and cancers.
• Bharat BiotechcoreOEM/ Whitelabel/ Licensing PartnerLicense agreements for Typhoid and Rotavirus vaccines already approved for human use, which can be manufactured and sold immediately by Innovative Biotech.
• Presidency of NigeriaflagshipStrategic or Co-development PartnerPresidential support expressed for local vaccine production aligning with government priorities. Special Adviser to the President on Health, Dr Salma Anas-Ibrahim, commended Innovative Biotech for commitment and perseverance spanning decades. Local vaccine production identified as top priority among eight key areas in the Ministry of Health.
• International Trade Centre (ITC)minorStrategic or Co-development PartnerWebsite development supported by ITC's Vaccine Investments and Trade Ecosystems in Africa project, funded by Ministry of Foreign Affairs of Japan.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Afrigen Biologics and Vaccines: South African biotech establishing African mRNA vaccine manufacturing capacity with the BioNTech partnership. Comparable as a fellow African vaccine-capacity builder, but competing on a different (mRNA) platform.
• Walvax Biotechnology: Chinese vaccine manufacturer with large-scale capacity and an Innovative Biotech ecosystem partner. Comparable on scale ambitions and a developing-country export focus.

Direct peers

• Institut Pasteur de Dakar: Senegalese vaccine manufacturer operating cGMP fill-finish and now expanding into large-scale vaccine production. The leading African-owned peer pursuing the same local-manufacturing thesis as Innovative Biotech.
• Bharat Biotech: Indian vaccine manufacturer and Innovative Biotech's licensor for Typhoid and Rotavirus vaccines. Most directly comparable because Innovative Biotech is effectively a localized manufacturing and sales extension of Bharat Biotech's portfolio across Africa.
• Biovac: South African vaccine manufacturer building local cGMP capacity for routine immunization antigens. Closest geographic peer and most direct competitor for African public-sector vaccine tenders.
• Biological E: Indian vaccine manufacturer with overlapping routine-immunization portfolio (including Typhoid conjugate and HPV). Competes in the same low-cost global tender markets Innovative Biotech will need to win in Africa.
• Panacea Biotech: Indian biotech producing vaccines including polio, DPT, and combination antigens. Listed as an Innovative Biotech ecosystem partner and a directly comparable emerging-market vaccine manufacturer.

Broad incumbents

• Sinovac / Sinopharm: Large Chinese vaccine manufacturers supplying inactivated COVID-19 and routine vaccines to African governments. Relevant incumbents competing for the same public-sector procurement contracts.
• Serum Institute of India: World's largest vaccine manufacturer by doses. Dominates African supply of routine immunization antigens Innovative Biotech plans to make, so the strategic benchmark and primary incumbent competitor.

Regional players

• Incepta Vaccine: Bangladeshi vaccine manufacturer and Innovative Biotech partner. Operates in the same emerging-market vaccine manufacturing segment targeting WHO-prequalified and Gavi-eligible markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innovative Biotech